In an extension of a phase II clinical drug trial, ustekinumab (Stelara®) was found to be a safe and effective treatment for lupus over two years of use. Researchers assessed multiple measures of ...

On December 1, 2024, Biocon announced that the FDA has approved YESINTEK™ (ustekinumab-kfce), a biosimilar to J&J’s STELARA®. YESINTEK is approved for the treatment of Crohn’s disease, Ulcerative ...

Ustekinumab is a monoclonal antibody, prescribed for psoriasis. The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught ...

CHICAGO — The anti-IL 12/23 p40 monoclonal antibody ustekinumab was associated with improved global and organ-specific systemic lupus erythematosus activity measures that were sustained through 1 year ...

Janssen announced new data from the phase 3 UNIFI maintenance study (N=523) which evaluated ustekinumab subcutaneous (SC) maintenance therapy in adults with moderate to severe ulcerative colitis (UC).

The monoclonal antibody ustekinumab (Stelara, Janssen Biotech Inc) induces response and remission in active moderate-to-severe Crohn's disease that is refractory to tumor necrosis factor (TNF) ...

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® ...

Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat. Lower response rates to ...

Please provide your email address to receive an email when new articles are posted on . Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized ...

Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian ...